

Appl No. 09/925,179
 Amend. dated September 7, 2004
 Response to Office Action mailed on: June 7, 2004

Patent Docket P0718P2C1D1C1

Amendments to the Claims:

This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims:

1-57. (Canceled)

58. (Previously presented). A humanized anti-IgE antibody comprising the variable heavy chain sequence and the variable light chain sequence of MAE11v1 (SEQ ID NOS: 8 and 9), wherein:

- (a) at least one light chain Kabat residues 13, 19, 58, 78 or 104 has been substituted;
 or
- (b) at least one heavy chain Kabat residues 48, 49, 60, 61, 63, 67, 69, 82 or 82c has been substituted.

59. (Previously presented). The antibody of Claim 58 which is an IgG1 antibody.

60. (Previously presented). The antibody of Claim 59, wherein heavy chain Kabat residue 60 has been substituted.

61. (Previously presented). The antibody of Claim 60, wherein residue 60 has been substituted with an amino acid residue selected from the group consisting of asparagine, glutamine, histidine, lysine and arginine.

62. (Previously presented). The antibody of Claim 59, wherein heavy chain Kabat residue 61 has been substituted.

63. (Previously presented). The antibody of Claim 62, wherein residue 61 has been substituted with an amino acid residue selected from the group consisting of proline, glycine, alanine, valine, leucine and isoleucine.

64. (Previously presented). The antibody of Claim 58, which is an IgG2 antibody.

Appl. No. 09/925,179
 Amend. dated September 7, 2004
 Response to Office Action mailed on June 7, 2004

Patent Docket **P0718P2C1D1C1**

65. (Previously presented). The antibody of Claim 64, wherein heavy chain Kabat residue 60 has been substituted.
66. (Previously presented). The antibody of Claim 65, wherein residue 60 has been substituted with an amino acid residue selected from the group consisting of asparagine, glutamine, histidine, lysine and arginine.
67. (Previously presented). The antibody of Claim 64, wherein heavy chain residue 61 has been substituted.
68. (Previously presented). The antibody of Claim 67, wherein residue 61 has been substituted with an amino acid residue selected from the group consisting of proline, glycine, alanine, valine, leucine and isoleucine.
69. (Previously presented). The antibody of Claim 58, which is an IgG3 antibody.
70. (Previously presented). The antibody of Claim 69, wherein heavy chain residue 60 has been substituted.
71. (Previously presented). The antibody of Claim 70 wherein residue 60 has been substituted with an amino acid residue selected from the group consisting of asparagine, glutamine, histidine, lysine and arginine.
72. (Previously presented). The antibody of Claim 69, wherein heavy chain residue 61 has been substituted.
73. (Previously presented). The antibody of Claim 72, wherein residue 61 has been substituted with an amino acid residue selected from the group consisting of proline, glycine, alanine, valine, leucine and isoleucine.

Appl. No. 09/925,179
Amend dated September 7, 2004
Response to Office Action mailed on: June 7, 2004

Patent Docket P0718P2C1D1C1

74. (Previously presented). The antibody of Claim 58 which is an IgG4 antibody.
75. (Previously presented). The antibody of Claim 74, wherein heavy chain residue 60 has been substituted.
76. (Previously presented). The antibody of Claim 75, wherein heavy chain residue 60 has been substituted with an amino acid residue selected from the group consisting of asparagine, glutamine, histidine, lysine and arginine.
77. (Previously presented). The antibody of Claim 74, wherein heavy chain residue 61 has been substituted.
78. (Previously presented). The antibody of Claim 77, wherein residue 61 has been substituted with an amino acid residue selected from the group consisting of proline, glycine, alanine, valine, leucine and isoleucine.